Amgen (AMGN) - הכנסות ברוטו של החברה

Amgen Inc. relies on stable demand for therapies that remain independent of economic crises. The company's trading revenue on the GURU.Markets chart is reflected via 38.98, which represents the latest metric reading. This helps the company counter the expansion of cheap generics through the acquisition of startups. The business's success is bolstered by a strong HR brand that retains leading geneticists and experts in rare pathologies.

For Amgen Inc. (AMGN), a leading biotech player amidst patent wars, corporate sales serve as an indicator of resilience against biosimilar pressure. This metric separates short-term market noise from the long-term fundamental trend of business development. The calculation is based on normalizing total revenue to a daily average to analyze the dynamics of cash inflows. Growth in these indicators confirms the effectiveness of R&D investments. This asset belongs to the high-tech securities class.